sweelin® is now FDA GRAS Approved, Clearing the Path for Accelerated U.S. Commercialization

sweelin® is now FDA GRAS Approved, Clearing the Path for Accelerated U.S. Commercialization

Amai Proteins announces a major milestone for sweelin® in the U.S. market. The U.S. FDA has completed its review of the GRAS (Generally Recognized as Safe) notice for sweelin® and confirmed it has no safety concerns regarding the use of sweelin® as...

Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort® Enteral Solution, Human Milk-Based Product in Japan

Clinigen Announces World-First Pharmaceutical Approval for Prolacta Bioscience's PreemieFort® Enteral Solution, Human Milk-Based Product in Japan

Clinigen obtained approval for Prolacta's "PreemieFort® Enteral Solution", a human milk-based fortifier, as an approved pharmaceutical product in Japan indicated for the "Nutritional management of neonates and infants presenting with weight gain...

Infineum P6188: Next Generation Additive Technology Approved Against Volkswagen's Latest Standards

Infineum P6188: Next Generation Additive Technology Approved Against Volkswagen's Latest Standards

ABINGDON, England, Feb. 6, 2026 /PRNewswire/ -- Infineum, a global leader in specialty chemicals for lubricants and fuels, has launched its new Volkswagen (VW) SAE 0W-20 product. Marketed as Infineum P6188, it is a next-generation product that...

ZEISS announces NMPA approval in China for powerful ophthalmic microscopes enhancing surgical visualization

ZEISS announces NMPA approval in China for powerful ophthalmic microscopes enhancing surgical visualization

ZEISS ARTEVO 750 and ZEISS ARTEVO 850 surgical microscopes provide ophthalmic surgeons in China with end-to-end workflow integration to improve efficiency, precision, and surgical safety. JENA, Germany and SHANGHAI, Feb. 3, 2026 /PRNewswire/ --...

Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases - A First for a Retinal Gene Therapy

Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases - A First for a Retinal Gene Therapy

Japan's Ministry of Health, Labour and Welfare (MHLW) grants MCO-010 Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations, enabling an accelerated regulatory pathway for patients with severe inherited retinal diseases...

AIM Vaccine's 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities

AIM Vaccine's 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities

HONG KONG, Jan. 20, 2026 /PRNewswire/ -- AIM Vaccine (06660.HK), a leading domestic vaccine company, announced on January 19 that it has developed an optimized upgraded version of its iterative 20-valent pneumococcal conjugate vaccine, which has...

Full Truck Alliance Co. Ltd. Announces Long-Term Shareholder Return Plan

Full Truck Alliance Co. Ltd. Announces Long-Term Shareholder Return Plan

GUIYANG, China, Jan. 19, 2026 /PRNewswire/ -- Full Truck Alliance Co. Ltd. ("FTA" or the "Company") (NYSE: YMM), a leading digital freight platform, today announced that, in order to carry out its long-term commitment to returning value to...

The AKG and Ca-AKG of Xin Tianhe have passed the US Self-GRAS certification

The AKG and Ca-AKG of Xin Tianhe have passed the US Self-GRAS certification

SHENZHEN, China, Jan. 16, 2026 /PRNewswire/ -- On January 7, 2026, the AKG and Ca-AKG of Xin Tianhe Biotechnology successfully completed the Self-GRAS scientific evaluation in accordance with the US FDA GRAS standards and were approved and became...

Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD

Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD

SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and...

Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD

Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD

SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 16
  • menu
    menu